Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PHLI Terminates Satietrol - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

PHLI Terminates Satietrol

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

PHLI Terminates Satietrol® Licensing Agreement
PacificHealth Laboratories, Inc. (PHLI), Woodbridge, NJ, has reacquired all rights to Satietrol® following the termination of a license agreement with GlaxoSmithKline (GSK), Research Triangle Park, NC. Satietrol is an appetite control product specifically designed to activate cholecystokinin (CCK), a peptide released by the body after eating that plays an important role in controlling ap­petite. GSK owns approximately 8.9% of the outstanding common stock of PHLI and has not indicated to PHLI any current intentions to decrease its holdings although GSK has no binding commitment with respect to the holding or sale of their shares in PHLI.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters